German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

被引：107

作者：

Nast, A. ^{[1
]}

Kopp, I. ^{[1
]}

Augustin, M. ^{[1
]}

Banditt, K. B. ^{[1
]}

Boehncke, W. H. ^{[1
]}

Follmann, M. ^{[1
]}

Friedrich, M. ^{[1
]}

Huber, M. ^{[1
]}

Kahl, C. ^{[1
]}

Klaus, J. ^{[1
]}

Koza, J. ^{[1
]}

Kreiselmaier, I. ^{[1
]}

Mohr, J. ^{[1
]}

Mrowietz, U. ^{[1
]}

Ockenfels, H. M. ^{[1
]}

Orzechowski, H. D. ^{[1
]}

Prinz, J. ^{[1
]}

Reich, K. ^{[1
]}

Rosenbach, T. ^{[1
]}

Rosumeck, S. ^{[1
]}

Schlaeger, M. ^{[1
]}

Schmid-Ott, G. ^{[1
]}

Sebastian, M. ^{[1
]}

Streit, V. ^{[1
]}

Weberschock, T. ^{[1
]}

Rzany, B. ^{[1
]}

机构：

[1] Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, dEBM, D-10117 Berlin, Germany

来源：

ARCHIVES OF DERMATOLOGICAL RESEARCH | 2007年 / 299卷 / 03期

关键词：

evidence-based guidelines; psoriasis vulgaris; treatment;

D O I：

10.1007/s00403-007-0744-y

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1-S126, 2006; or http://www.psoriasis-leitlinie.de).

引用

页码：111 / 138

页数：28

共 150 条

[21] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].

Chaudhari, U ;

Romano, P ;

Mulcahy, LD ;

Dooley, LT ;

Baker, DG ;

Gottlieb, AB .

LANCET, 2001, 357 (9271) :1842-1847

[22]

Chuang TY, 1991, J DERMATOL TREAT, V2, P63

[23]

COLLINS P, 1992, BRIT J DERMATOL, V127, P392

[24]

Cooper EJ, 2000, CLIN EXP DERMATOL, V25, P111

[25] Safety and efficacy study on etanercept in patients with plaque psoriasis [J].

Costanzo, A ;

Mazzotta, A ;

Papoutsaki, M ;

Chimenti, S .

BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (01) :187-189

[26] Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B [J].

Coven, TR ;

Burack, LH ;

Gilleaudeau, P ;

Keogh, M ;

Ozawa, M ;

Krueger, JG .

ARCHIVES OF DERMATOLOGY, 1997, 133 (12) :1514-1522

[27]

de Mare S, 1988, Skin Pharmacol, V1, P259

[28]

Decroix J, 2004, CUTIS, V74, P201

[29] PSORALENS AND UV-A AND UV-B TWICE WEEKLY FOR THE TREATMENT OF PSORIASIS [J].

DIETTE, KM ;

MOMTAZT, K ;

STERN, RS ;

ARNDT, KA ;

PARRISH, JA .

ARCHIVES OF DERMATOLOGY, 1984, 120 (09) :1169-1173

[30] ROLE OF ULTRAVIOLET-A IN PHOTOTHERAPY FOR PSORIASIS [J].

DIETTE, KM ;

MOMTAZT, K ;

STERN, RS ;

ARNDT, KA ;

PARRISH, JA .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 11 (03) :441-447

← 1 2 3 4 5 6 7 8 9 10 →